Cytodyn is the Clevelend Browns of Bio Tech…
“NP mis-managed the company badly, but this is a fundamentally different company now. Methodical, sober and going quietly about their business”.
The only fundamentals that have changed is more dilution. Nader completely wasted $400 to $500m and massive dilution with a drug trial for HIV that will be dated by 5 years at least, if the BLA even gets submitted next year. There are no trials going on and little cash. Certainly better off without Nader, but the massive debt and looming alphabet soup investigation make this a fundamentally worse off company than 2019 or even early 2020. Current management has a steep hill to climb.
News 
Market Data 
Discover 
